ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0076

Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them

AASTHA KHULLAR1, Varun Dhir2, Leishangthem Bidyalaxmi1, Chandra Bhushan Prasad3, Sankar Jayaprakash1, Siddharth Jain4, Biman Saikia1, Aman Sharma5, Shefali Sharma6, Ashok Kumar Yadav1, Shankar Naidu1 and Sanjay Jain7, 1PGIMER, Chandigarh, India, 2PGIMER, CHD, INDIA, Chandigarh, India, 3Healthway Hospital, Goa, Zuarinagar, India, 4AIIMS, Delhi, India, 5PGIMER, Chandigarh, India, Chandigarh, India, 6PGIMER< Chandigarh, Chandigarh, India, 7Post Graduate Institute of Medical Education and Research, Chandigarh, India

Meeting: ACR Convergence 2023

Keywords: rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Background: GMCSF producing T-cells may be implicated in the pathogenesis of autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriatic arthritis. Few studies reported higher frequencies of CD4+GMCSF+ T-cells in the MS lesions and RA synovial fluid; however, there is no data on CD8+GMCSF+ T-cells. Thus, we planned to assess their frequencies in blood and synovial fluid, and characterize based on polyfunctionality, phenotype, cytotoxic ability and the effect of methotrexate on them.

Methods: The frequency of GMCSF producing CD8 and CD4 T-cells was assessed by stimulation with PMA/Ionomycin, followed by immunostaining and flowcytometry. Subsequently, polyfunctionality for other cytokines (TNFα, IFNγ and IL-17), memory/naïve phenotype and perforin/granzyme expression was also assessed by flowcytometry

Results: Enrichment of GMCSF producing T-cells was found in the synovial fluid, with elevated frequencies of both CD8+GMCSF+ T-cells (5.8, 3.9%, p= 0.0045) and CD4+GMCSF+ T-cells (8.5, 4.5%, p=0.0008) compared to peripheral blood. These cells were characterised as extremely polyfunctional, with higher frequencies of triple cytokine positive GMCSF+TNFα+IFNγ positive CD8 T-cells (81, 36%, p=0.049) and CD4+GMCSF+TNFα+IFNγ+ (48, 32%, p=0.01)) in synovial fluid compared to blood. Majority of GMCSF producing T-cells had an effector memory (EM) phenotype, besides CD8+GMCSF+ T-cells also having increased expression of granzyme B. After MTX treatment, there was a significant reduction in circulating CD4+ T-cells producing GMCSF (4.6% to 2.9%, p= 0.0014) and a similar trend was seen in the CD8 T (3.7% to 2.9% p= 0.068) cells.

Conclusion: Synovial fluid enrichment with GMCSF producing CD8 T-cells (and CD4 T-cells) was observed, demonstrating elevated polyfunctionality and granzyme B expression with majority belonging to EM phenotype. Upon treatment with methotrexate a reduction in the frequencies of these cells was found.

Supporting image 1


Disclosures: A. KHULLAR: None; V. Dhir: None; L. Bidyalaxmi: None; C. Prasad: None; S. Jayaprakash: None; S. Jain: None; B. Saikia: None; A. Sharma: None; S. Sharma: None; A. Yadav: None; S. Naidu: None; S. Jain: None.

To cite this abstract in AMA style:

KHULLAR A, Dhir V, Bidyalaxmi L, Prasad C, Jayaprakash S, Jain S, Saikia B, Sharma A, Sharma S, Yadav A, Naidu S, Jain S. Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/characterizing-gmcsf-producing-t-cells-in-rheumatoid-arthritis-and-effect-of-methotrexate-on-them/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-gmcsf-producing-t-cells-in-rheumatoid-arthritis-and-effect-of-methotrexate-on-them/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology